Quantcast
Channel: Multiple Myeloma News – The Myeloma Crowd

ASH 2019: Minimal Residual Disease as a New Clinical Trial End Point

0
0
Minimal Residual Disease (MRD) testing is a way of testing how much disease is left after myeloma therapy. MRD testing is now being used more often in the clinic to gauge how well a treatment worked and researchers are hopeful that MRD testing will help clinical trials move along faster. With more myeloma therapies in [...]

Will a Failed Alzheimers Drug Further Improve Anti-BCMA CAR-T in Multiple Myeloma?

0
0
There already is much excitement in the multiple myeloma community about the possibility of FDA-approval for one or more anti-BCMA CAR-T products in the coming 12-24 months. Early data that have been published offer hope to many of us. There is a common thread, though, in the data seen so far. The products in late [...]

Myeloma Highlights From ASH: Jack Aiello’s Super Summary

0
0
According to myeloma patient advocate Jack Aiello (definitely not medically trained) (Glossary of terms are below) PREFACE This is my 14th year attending ASH (American Society of Hematology), where over 30,000 attendees from all over the world (hematologists/oncologists, lab researchers, oncology nurses, scientists & 300 pharma companies) present the latest research results via both oral [...]

ASH 2019: Chemotherapy Melflufen Moves Through Myeloma Clinical Trials

0
0
Many myeloma patients are familiar with the chemotherapy called melphalan, which is regularly used as part of the stem cell transplant process. A Swedish company called Oncopeptides AB is developing a new type of similar, but different therapy, that improves the impact of the drug while lowering side effects. Melflufen is also a chemotherapy, but [...]

What is the Myeloma Crowd Research Initiative (MCRI)?

0
0
  The Myeloma Crowd Research Initiative (MCRI) is a new approach to funding cancer research; combining the skill and knowledge of leading myeloma specialists with the patient perspective and supportive patient social communities to select and fund promising research projects in myeloma. A small fraction of multiple myeloma patients may already be cured but researchers [...]

A Single T Cell Therapy for All Cancers? British Researchers Make a Key Discovery.

0
0
Cardiff University researchers have discovered a new a new type of T cell that can kill a variety of cancers, with the hope of creating a general "one-size-fits-all" T cell therapy.  CAR T cell therapy today is commonly "customized" for each cancer patient using their own T cells. A patient has their immune system cells [...]

Multiple Myeloma Treatment and Secondary Cancers

0
0
It is fair to say that, from multiple myeloma chat groups, support groups, blogs, etc. we have heard or read stories (or, heaven forbid, from personal experience) that fellow patients have come down with a ‘treatment related secondary cancer’. In our case, the majority of those will be skin cancers (basal and squamous cell carcinomas), [...]

Sanofi and Sebia Develop New Monoclonal Protein Detection Test in Multiple Myeloma

0
0
In myeloma, it is known that patients who are taking monoclonal antibodies that target CD38 can have "detectable" levels of a monoclonal protein, when those levels are actually related to the monoclonal antibody itself. This can confuse patients and their doctors who could believe that they still have detectable myeloma when they in fact do [...]

Reducing CAR T Side Effects in Multiple Myeloma

0
0
New immunotherapies in myeloma called CAR T therapy use a patient's own genetically-engineered T cells to attack the tumor. This breakthrough therapy is making its way through the FDA approval process in myeloma and is exciting for myeloma patients. The therapy does have some challenges - because it is customized, it is expensive and complex [...]

Good News for Myeloma Patients: Steadily Improving Outcomes With “Total Therapy”

0
0
The most recent issue of the journal Blood Advances provides us, myeloma patients, with good news. The article presents long-term follow-up data of over 4,300 patients from the University of Arkansas for Medical Sciences (UAMS) with newly diagnosed MM who were treated ‘in a uniform fashion [and]who have undergone long-term follow-up’. A ‘uniform fashion’ means [...]




Latest Images